NSE · JAGSNPHARM · Healthcare
Jagsonpal Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹81 Cr with net profit ₹13 Cr — a 15.47% net margin, versus 16.04% the period before.
Shareholding
As of 2026-09-30
- Promoter68.81%
- Public29.04%
- FII2.14%
- DII0%
26,537 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.71× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #6 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | ₹17,961 Cr | 26.09 | 4.94 | 18.44% | 24.95% |
| Astrazeneca Pharma India Ltd. | ₹15,079 Cr | 80.11 | 17.18 | 20.22% | 6.83% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹11,664 Cr | 30.9 | 3.33 | 10.39% | 7.54% |
| Procter & Gamble Health Limited | ₹9,643 Cr | 27.07 | 14.69 | 57.72% | 25.48% |
| Gujarat Themis Biosyn Ltd. | ₹5,058 Cr | 108.26 | 6.69 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd.(this company) | ₹1,428 Cr | 30.23 | 5.85 | 18.66% | 15.13% |
| Bafna Pharmaceuticals Ltd. | ₹1,140 Cr | 98.98 | 11.1 | 11.15% | 7.44% |
| Bajaj HealthCare Limited | ₹1,089 Cr | 18.71 | 1.95 | 10.45% | 3.14% |
| Amanta Healthcare Limited | ₹910 Cr | 49.68 | 4 | 8.04% | 6.04% |
| Anuh Pharma Limited | ₹826 Cr | 17.29 | 2.3 | 13.27% | 6.14% |
AI analysis
AI-generated · google/gemini-2.5-flashJagsonpal Pharmaceuticals Ltd. has a market capitalization of Rs 1470 Cr. The company reported revenue of Rs 276.91 Cr and a profit margin of 15%. Its earnings per share (EPS) is Rs 6.77. The 52-week high for the share price was Rs 301.65 and the 52-week low was Rs 155.
Positives
- +The company's return on capital employed (ROCE) is 20.5904%.
- +The debt-to-equity ratio is low at 0.04.
- +Promoter shareholding is at 69.3604% as of Jun 2026.
- +Annual net profit increased from Rs 17.0583 Cr in Mar 2021 to Rs 55.361 Cr in Mar 2025.
Negatives
- −The trailing twelve months PE ratio is 178.42.
- −The company's earnings per share (EPS) decreased from Rs 10.2 in Mar 2023 to Rs 3.39 in Mar 2024.
- −The public shareholding increased from 27.8725% in Jun 2022 to 30.8263% in Jun 2018 (this is reverse chronological data; should be phrased carefully).
- −No revenue growth percentage is available.
Financial performance
Jagsonpal Pharmaceuticals Ltd. reported an increase in annual revenue from Rs 192.3389 Cr in Mar 2021 to Rs 276.906 Cr in Mar 2025. Annual net profit also rose from Rs 17.0583 Cr in Mar 2021 to Rs 55.361 Cr in Mar 2025. Diluted EPS has shown fluctuations, reaching Rs 10.2 in Mar 2023 before decreasing to Rs 3.39 in Mar 2024 and then rising to Rs 8.22 in Mar 2025. The company's highest quarterly revenue was Rs 75.61 Cr in Jun 2025, and highest quarterly net profit was Rs 31.99 Cr in Dec 2024.
Profitability & returns
The company recorded a return on equity (ROE) of 15.6% and a return on capital employed (ROCE) of 20.5904%. The profit margin for the latest period stood at 15%. Over the past five annual periods, EBITDA has increased from Rs 22.3858 Cr in Mar 2021 to Rs 51.13 Cr in Mar 2025. However, quarterly net profit in Mar 2026 was Rs 8.76 Cr, lower than the Rs 31.99 Cr reported in Dec 2024.
Balance sheet
Jagsonpal Pharmaceuticals Ltd. has a debt-to-equity ratio of 0.04, indicating a low level of debt relative to its equity. The book value per share is Rs 41.86. The company paid a dividend of 182%, based on the reported dividend yield. The market capitalization is Rs 1470 Cr.
Ownership & pledges
As of Jun 2026, promoters held 69.3604% of the shares. Public shareholding was 27.8725%. FIIs held 2.4558% and DIIs held 0.3113%. Institutions collectively held 2.7671%. There has been a slight increase in promoter holding from 69.1706% in Jun 2018 to 69.3604% in Jun 2026. The number of shareholders rose from 9923 in Jun 2018 to 24824 in Jun 2026. There are no promoter pledged shares reported.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Jagsonpal Pharmaceuticals Ltd.share price & fundamentals